Three presidents meet in Shenzhen this week. Donald Trump, Xi Jinping and Vladimir Putin gathered to discuss nuclear arms, international security and the balance of global power. Comparisons with Yalta in 1945 were inevitable. Eight decades later, the world’s major powers are again exploring how international relationships might be reshaped, while others contemplate the consequences of decisions made without them.
Shenzhen is not Yalta. One meeting does not establish a new world order. But it raises an uncomfortable question for Europe: who defines the priorities, who controls the resources, and who is left outside the room?
The implications extend far beyond defence and diplomacy.
Germany’s efforts to secure durable financing for Ukraine within the European Union’s next long-term budget demonstrate the political determination that governments can mobilise when they regard an issue as strategically essential. Berlin wants commitments that will survive changes in governments and political majorities.
But why should governments not apply the same determination to health?
This is not an argument for choosing healthcare over defence. Both are fundamental to security and resilience. Yet while governments explore mechanisms to protect long-term geopolitical commitments, cancer prevention, advanced diagnostics, laboratory infrastructure and access to innovative treatments remain vulnerable to fragmented budgets and political cycles.
Europe speaks frequently about strategic autonomy, competitiveness and technological sovereignty. But what does technological leadership mean if patients cannot access the tests, expertise and treatments that innovation makes possible?
Meanwhile, another contest for international leadership is unfolding in Geneva.
This week, seven candidates for the next Director-General of the World Health Organization are presenting their visions to Member States. The discussions expose a fundamental tension: governments demand greater financial discipline from international institutions while simultaneously expecting them to respond to increasingly complex global health challenges.
Among the candidates is Dr María Neira, a member of IAPM’s Board, nominated by Spain. Her participation brings the debate particularly close to our international network. The forthcoming WHO leadership transition is more than an institutional election. It is an opportunity to examine what global health cooperation should deliver, how it should be financed and whether international commitments can survive growing geopolitical divisions.
The real test of global health leadership is not simply who occupies the highest office, but whether political commitments translate into functioning healthcare systems.
That question also took centre stage last week in Changsha.
At the Chinese Congress on Holistic Integrative Oncology, IAPM and the China Anti-Cancer Association brought together Chinese and international expertise to examine how scientific innovation becomes clinical reality. The discussions connected molecular diagnostics, artificial intelligence, regulatory evidence, laboratory readiness, clinical trials, financing and patient access.
China’s clinical scale and growing innovation capacity create important opportunities for international cooperation. But exchanging research and technologies is no longer sufficient. Cooperation must deliver shared standards, stronger clinical pathways and measurable improvements in patient care. This is the ambition behind IAPM’s proposed Advanced Diagnostics and AI Delivery Compact.
And this week’s scientific developments show why such cooperation matters.
In the United States, a newly approved breast cancer treatment depends on a liquid-biopsy result to determine patient eligibility. Europe is moving towards integrating predictive diagnostics throughout a medicine’s regulatory lifecycle. Advances in artificial intelligence, molecular medicine and earlier intervention are opening extraordinary possibilities.
Yet the scientific breakthrough is increasingly only the beginning. Without access to testing, clinical interpretation, financing and treatment, personalised medicine risks becoming another source of healthcare inequality.
There is a striking contradiction at the heart of the changing international order.
Governments are increasingly competing for geopolitical influence, while medical progress depends more than ever on international cooperation.
Cancer does not recognise geopolitical boundaries. Neither do Alzheimer’s disease, antimicrobial resistance or the challenges of ageing populations. Geography, however, still determines whether patients can access the innovations that might improve or save their lives.
Shenzhen illustrates the politics of global power. Geneva confronts the future of global health leadership. Changsha demonstrated how international scientific cooperation can be directed towards practical implementation.
The next geopolitical order may be shaped by those sitting around the negotiating table. But the next era of personalised medicine will be judged by whether patients benefit from the decisions that follow.
The pathway is becoming the product. And the ability to deliver it is becoming the real test of health policy.
This week
- A global cancer drug hits the FDA’s evidence border | Ivonescimab’s rejection puts trial geography, survival and toxicity under one hard regulatory test.
- Europe clears a RAS drug; access becomes a national decision | A substantial pancreatic-cancer survival result now enters 27 reimbursement systems.
- Pfizer pays early for China’s in vivo CAR-T platform | Three preclinical autoimmune programmes carry a $330 million upfront commitment.
- Washington wants its reviews to travel | The FDA plans to share more of its scientific assessments with regulators abroad.
- An AML vaccine clears the survival test | A phase III result offers a possible maintenance treatment after a second remission.
- GSK’s $10.6 billion lung-cancer bet delivers again | Its second Nuvalent asset receives an accelerated US approval for ALK-positive disease.
- Two rare diseases, two different routes to evidence | New FDA decisions address survival in Niemann-Pick disease and neurological symptoms in Gaucher disease.
- AI drug discovery raises $5 billion before its first trial | Isomorphic’s financing raises the stakes for clinical validation.
- The HPV test exists. The screening gap remains enormous | New WHO estimates expose a stark divide in access to cervical-cancer prevention.
- Europe’s resistant bacteria are outrunning treatment options | ECDC calls for faster laboratory detection and coordinated control of a worsening threat.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
A global cancer drug hits the FDA’s evidence border
The FDA has declined to approve ivonescimab plus chemotherapy for a group of patients with previously treated EGFR-mutated non-small-cell lung cancer. Its complete response letter says that 257 of 275 progression-free survival events—93%—occurred among patients enrolled in China, limiting the agency’s ability to establish how that endpoint applied to the US population. The FDA also found no statistically significant overall-survival improvement, judged the progression-free survival gain modest against the additional toxicity, and recommended a new, adequately controlled multiregional trial demonstrating meaningful clinical benefit. (FDA’s complete response letter)
This is a consequential decision for companies licensing medicines across borders. The FDA did not declare Chinese clinical research unacceptable; it identified specific problems with where events occurred, what the trial proved and whether the benefit outweighed the risk. Trial geography cannot be repaired by a commercial agreement after the pivotal data are collected. International development needs representative enrolment and an agreed evidentiary strategy from the outset—and patients need a result that answers more than whether a scan changed.
Europe clears a RAS drug; access becomes a national decision
The European Commission authorised Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic treatment. In the multinational phase III trial of 500 patients, median overall survival was 12.4 months, compared with 6.7 months on chemotherapy; median progression-free survival was 7.2 versus 3.6 months. The EU indication does not require an identified RAS mutation, although 92% of trial participants had a confirmed RAS G12 mutation. The decision, taken on 16 November, is a major development that was absent from issue 45. (Commission authorisation; EMA’s trial review)
The approval shows what compelling survival evidence can do in a cancer with few options after treatment failure. It also exposes Europe’s next divide. The authorisation applies across the EU, while price and reimbursement decisions remain national; the company says the timing of patient access will vary by country. Regulators have opened the door. Governments and payers now determine how many eligible people can walk through it—and how quickly.
Pfizer pays early for China’s in vivo CAR-T platform
Pfizer has licensed three pre-IND in vivo CAR-T programmes for autoimmune diseases from China’s Starna Therapeutics. It will pay $330 million upfront, with up to $2.3 billion more tied to milestones, plus potential royalties. The principal development and commercial rights are outside Greater China; Pfizer also has options concerning that territory and will lead initial clinical development outside it. None of the three programmes has yet entered the trials needed to establish patient benefit. (Pfizer’s announcement)
The deal is about more than one pipeline purchase. Starna’s targeted lipid nanoparticle and RNA technology aims to generate CAR-T cells inside the body, potentially changing how cell therapies are made and delivered if clinical testing succeeds. Pfizer is paying for an early position in that possibility, while planning to manufacture product for the initial trials in the United States. The commercial route is already international. The evidence, manufacturing controls and eventual access model still have to be built.
Washington wants its reviews to travel
The FDA announced a Global Reliance Disclosure Program that lets eligible applicants obtain minimally redacted approval packages—including the agency’s scientific assessments—for submission to regulators outside the United States. The programme currently covers specified PEPFAR tentative approvals. The FDA intends to expand it to all novel drugs and biologics in January 2027, while foreign authorities retain responsibility for their own decisions. (FDA’s announcement)
This could reduce duplicated regulatory work where review capacity is stretched. It is also an assertion of influence: a US assessment may become part of another country’s route to approval. Reliance can shorten a review, but it cannot settle local questions about clinical relevance, diagnostic capacity, price or supply. The real measure of this policy will be whether sharing evidence helps other regulators make timely, independent decisions—and whether those decisions result in treatment reaching patients.
An AML vaccine clears the survival test
Galinpepimut-S, an investigational vaccine targeting WT1, met the overall-survival endpoint in the phase III REGALtrial. Among 126 patients with acute myeloid leukaemia who had reached a second or later remission and could not undergo an allogeneic stem-cell transplant, median overall survival was 24.0 months with the vaccine versus 14.7 months with investigator-selected care. The reported hazard ratio was 0.59. The findings are topline company results; detailed analyses have yet to be presented and peer reviewed, and the vaccine is not approved. (SELLAS’s trial announcement)
The result matters because remission after relapse is often fragile, and this group has limited maintenance options. Unlike a vaccine made separately from each person’s tumour, this is an off-the-shelf approach directed at a shared cancer antigen. The survival endpoint gives regulators and clinicians something substantial to assess. The next decisions will turn on the full dataset, safety, the exact eligible population and whether the reported benefit holds up under review.
GSK’s $10.6 billion lung-cancer bet delivers again
The FDA granted accelerated approval to Nelkarmi (neladalkib) for specified adults with previously treated ALK-positive advanced non-small-cell lung cancer. In the single-arm ALKOVE-1 study, the confirmed response rate was 49% among 67 patients who had previously received alectinib as their only ALK inhibitor, and 32% among 155patients who had received at least two ALK inhibitors and platinum chemotherapy. It is the second US lung-cancer approval from the portfolio GSK acquired with Nuvalent in a transaction valued at approximately $10.6 billion (FDA’s approval; GSK’s acquisition announcement)
For patients whose ALK-driven cancer has progressed despite targeted therapy, another treatment option is meaningful. For GSK, the decision strengthens the industrial case for buying a portfolio built around molecularly defined disease. Accelerated approval here rests on response and duration of response, rather than an established survival advantage. The larger test is whether patients receive timely ALK testing, whether the benefit proves durable, and how the medicine fits into an increasingly crowded treatment sequence.
Two rare diseases, two different routes to evidence
The FDA made two rare-disease decisions within two days. Lembaz (adrabetadex) was approved to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C who meet the specified weight and symptom-onset criteria. The agency compared 36 treated patients with matched external controls and reported a 55% lower risk of death; median survival was 8.5 versus 4.9 years in those groups. The following day, the FDA approved Infilbray (venglustat) as the first treatment for the neurological symptoms of type 3 Gaucher disease, supported by a randomised study involving 43 patients. (FDA on Niemann-Pick disease; FDA on Gaucher disease)
These are distinct claims supported by distinct forms of evidence: survival against external controls in one severe childhood-onset condition, and improvement on neurological assessments in a randomised comparison in the other. Neither decision removes the need for careful follow-up. Lembaz requires an injection into the spinal canal every two weeks and carries a boxed warning for hearing impairment, including permanent loss; Infilbray’s risks include serious psychiatric effects. Rare-disease policy must make room for feasible studies while remaining exact about what each treatment has—and has not—shown.
AI drug discovery raises $5 billion before its first trial
Isomorphic Labs announced a $5 billion Series C financing round led by Greenoaks and Sequoia Capital, with participation from Alphabet and other investors. The company says the funding will expand its AI drug-design engine, its internal and partnered pipeline, and the infrastructure needed to take candidates into clinical trials. Its disclosed progress includes preclinical programmes in oncology and immunology; this financing is not a clinical efficacy result. (Isomorphic’s announcement)
The size of the round changes the industrial conversation. Investors are funding AI drug discovery at a scale capable of supporting models, laboratories, development teams and trials—not simply software demonstrations. That creates an equally large obligation to show which predictions survive experimental and clinical testing. Faster molecular design would matter to patients if it produces medicines with demonstrable benefit, credible safety and a route into care.
The HPV test exists. The screening gap remains enormous
New WHO estimates indicate that three in five women aged 30–49 have never been screened for cervical cancer. The divide is especially stark for HPV testing: only 2% of women in low- and middle-income countries had received an HPV test in the preceding five years, compared with 32% in high-income countries. WHO also reported progress, including public-system HPV DNA testing in 26 of Brazil’s 27 federal units, alongside efforts to expand screening and treatment in other regions. (WHO’s update)
This is the most direct patient-access test in the brief. A highly effective screening technology has little value to a woman who never encounters the service, and a positive result has little value without follow-up and treatment. Governments can count tests purchased; they need to count women reached, results returned and precancers treated. Cervical-cancer elimination will be won or lost in the connection between those steps.
Europe’s resistant bacteria are outrunning treatment options
In a new risk assessment, the European Centre for Disease Prevention and Control says the situation for carbapenem-resistant Enterobacterales is worsening across the EU and EEA. It identifies increasing incidence of bloodstream infection caused by resistant Klebsiella pneumoniae, a rising share of NDM resistance mechanisms and a shrinking set of effective treatment options. ECDC rates the probability of further spread as high and warns of a very high risk to patients who require healthcare. (ECDC’s risk assessment)
Issue 45 examined the gap between national antimicrobial-resistance plans and functioning laboratories. This assessment shows what that gap can cost. ECDC calls for rapid detection and characterisation, including identification of resistance genes, near-real-time genomic surveillance, infection control and access to treatments active against NDM-producing organisms. For a patient facing chemotherapy, transplantation or intensive care, laboratory capacity and infection prevention are part of the treatment pathway.
The November watch
| 19–20 November · Geneva: |
| WHO Global Clinical Trials Forum meets on stronger trial systems and international cooperation. |
| 25 November · Geneva: |
| WHO–WIPO–WTO symposium examines local health-product manufacturing, trade, intellectual property and AI. Registration closes 23 November. |
| 27 November · Online: |
| EMA’s ACT EU workshop examines how to assess evidence from two-arm and platform trials. |
| 29–30 November · Doha: |
| WISH 2026 brings early diagnosis, AI governance and financing for breakthrough therapies into the health-policy discussion. |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.

International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium

